Priority review for Taxotere in head and neck cancer (PharmaBiz)
Sanofi-aventis announced that the US Food and Drug Administration (FDA) has accepted for filing and assigned priority review status to the supplemental new drug application (sNDA) for Taxotere (docetaxel) Injection Concentrate in combination with cisplatin and fluorouracil for the induction (neo-adjuvant) therapy of patients with locally advanced squamous cell carcinoma of the head and neck ...

Taxotere(R) (docetaxel) Granted FDA Priority Review For Treatment Of Locally Advanced Squamous Cell Carcinoma Of The ... (Medical News Today)
Sanofi-aventis announced today that the U.S. [click link for full article]

Natco gets US FDA approval for ondansetron tabs (PharmaBiz)
Natco Pharma Ltd has informed that the company's application for abbreviated new drug (ANDA) for ondansetron hydrochloride tablets in multiple strengths 4 mg and 8 mg has been approved by the US Food and Drug Administration.